Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04374253 · ClinicalTrials.gov registry record · Phase 3
A Study to Evaluate the Safety, Tolerability, and Efficacy of Long-Term Gantenerumab Administration in Participants With Alzheimer's Disease (AD)
A Phase 3 study, sponsored by Hoffmann-La Roche.
- Terminated
- Registry status
- Phase 3
- Development phase
- 1,382
- Enrollment target
NCT04374253 is a Phase 3 study that was terminated before completion, run by Hoffmann-La Roche. The registered enrollment target is 1,382 participants.
The verdict
NCT04374253, a Phase 3 study, was terminated before completion, sponsored by Hoffmann-La Roche.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 1,382 participants
- Enrollment target
Study Summary
This is an open-label, multicenter, rollover study to evaluate the safety, tolerability, and efficacy of long-term administration of open-label gantenerumab in participants with AD who completed Study WN29922 or WN39658, either the double-blind or open-label extension (OLE) part.
Interventions
- DRUG Gantenerumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,382 participants |
| Start Date | 2021-01-26 |
| Est. Completion | 2023-03-06 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04374253
The ClinicalTrials.gov registry entry for NCT04374253 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 1,382 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Hoffmann-La Roche, which has 909 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Gantenerumab is the first listed.
NCT04374253 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04374253 about?
NCT04374253 is a clinical study titled "A Study to Evaluate the Safety, Tolerability, and Efficacy of Long-Term Gantenerumab Administration in Participants With Alzheimer's Disease (AD)". This is an open-label, multicenter, rollover study to evaluate the safety, tolerability, and efficacy of long-term administration of open-label gantenerumab in participants with AD who completed Study WN29922 or WN39658, either the double-blind or open-label extension (OLE) part.
What is the current status of trial NCT04374253?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 1,382 participants. The study started on 2021-01-26. Estimated completion is 2023-03-06.
What interventions are being tested in trial NCT04374253?
The interventions under investigation include: Gantenerumab (DRUG).
Who is sponsoring clinical trial NCT04374253?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.